Literature DB >> 27330784

Long term follow-up of surgery management of prostate leiomyosarcoma metastasized to the rib: A case report and literature review.

Wei Chen1, Deng-Jun Han1, Guang-Qing Fu1, Wei Lin1, Yong Liang1.   

Abstract

Prostate sarcoma, particularly the pathological type of leiomyosarcoma, is a rare carcinoma, which originated from the interstitial tissue of the prostate. This sarcoma type has a poor prognosis. This disease accounts for ~0.1% of all prostate cancer and it usually occurrs in patients aged between 40 and 78-years-old. Although prostate leiomyosarcoma has a poor prognosis, early treatment of post-operative recurrence and metastases via a whole-body examination and closer follow-up was possible. These measurements may significantly prolong the survival time and improve the quality of life. The present study reported a successful case of surgical management for prostate leiomyosarcoma in the Zigong No. 4 People's Hospital (Sichuan, China) during 1995 until 2015, with post-operative follow-up for 20 years.

Entities:  

Keywords:  immunohistochemistry; leiomyosarcoma; prognosis; prostate; sarcoma

Year:  2016        PMID: 27330784      PMCID: PMC4906952          DOI: 10.3892/mco.2016.898

Source DB:  PubMed          Journal:  Mol Clin Oncol        ISSN: 2049-9450


  13 in total

1.  Primary leiomyosarcoma of the prostate with lung metastasis: report of a case diagnosed by fine-needle aspiration cytology.

Authors:  Adarsh Barwad; Niranjan Khandelwal; Sameer Vyas; Dhrubajyoti Gogoi; Pranab Dey
Journal:  Diagn Cytopathol       Date:  2010-11-15       Impact factor: 1.582

2.  Phase I/II study of docetaxel, ifosfamide, and doxorubicin in advanced, recurrent, or metastatic soft tissue sarcoma (STS).

Authors:  Revathi Suppiah; Laura Wood; Paul Elson; George T Budd
Journal:  Invest New Drugs       Date:  2006-11       Impact factor: 3.850

3.  Specialized stromal tumors of the prostate: a clinicopathologic study of 50 cases.

Authors:  Mehsati Herawi; Jonathan I Epstein
Journal:  Am J Surg Pathol       Date:  2006-06       Impact factor: 6.394

4.  Sarcomatoid Carcinoma of the Prostate: Retrospective Review of a Case Series From the Johns Hopkins Hospital.

Authors:  Mark C Markowski; Mario A Eisenberger; Marianna Zahurak; Jonathan I Epstein; Channing J Paller
Journal:  Urology       Date:  2015-06-28       Impact factor: 2.649

Review 5.  Evolution of the surgical management of pulmonary metastases.

Authors:  N Martini; P M McCormack
Journal:  Chest Surg Clin N Am       Date:  1998-02

6.  Recurrent episodes of hematuria: a rare presentation of leiomyosarcoma of prostate.

Authors:  Kaustav Talapatra; Bhushan Nemade; Ritu Bhutani; Shubhada Kane; Ashish Bakshi; Mary Ann Muckaden; Siddhartha Laskar
Journal:  J Cancer Res Ther       Date:  2006 Oct-Dec       Impact factor: 1.805

Review 7.  Mesenchymal tumours of the bladder and prostate: an update.

Authors:  Fabio Tavora; Oleksandr N Kryvenko; Jonathan I Epstein
Journal:  Pathology       Date:  2013-02       Impact factor: 5.306

Review 8.  [Leiomyosarcoma of the prostate: a case report of remission for 9 years by radiotherapy].

Authors:  Y Sakano; J Yonese; Y Okubo; K Yoshimura; H Maeda; T Yamauchi; I Fukui; T Kawai; Y Ishikawa
Journal:  Hinyokika Kiyo       Date:  1995-08

9.  Sarcoma of the prostate: a single institutional review.

Authors:  Nguyen L Janet; Abdel-Wahab May; Robin S Akins
Journal:  Am J Clin Oncol       Date:  2009-02       Impact factor: 2.339

10.  Leiomyosarcoma of the prostate: case report and review of 54 previously published cases.

Authors:  Gerasimos P Vandoros; Theodoros Manolidis; Michalis V Karamouzis; Maria Gkermpesi; Maria Lambropoulou; Athanasios G Papatsoris; Ioannis Zachos; Panagiotis A Konstantinopoulos
Journal:  Sarcoma       Date:  2008-11-18
View more
  1 in total

1.  Prostatic leiomyosarcoma in a dog treated using a multimodal approach.

Authors:  Marco Trovatelli; Jessica Bassi; Chiara Giudice; Roberta Ferrari; Maurizio Longo; Stefano Brizzola
Journal:  J Vet Intern Med       Date:  2021-02-24       Impact factor: 3.333

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.